Quantcast

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

March 16, 2009

BETHESDA, Md., March 16 /PRNewswire-FirstCall/ — Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of six abstracts for poster presentations at the 100th annual meeting of AACR taking place from April 20-24, 2009, in Denver, Colorado.

The following posters will be presented:

  1. Lutterbuese, R. et al. (2009). Highly efficient lysis of KRAS- and BRAF-mutated human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab. AACR Annual Meeting 2009, abstract no. 3251; to be presented in session ‘Immunology 5′ on April 21, 2009, 8:00 AM in Hall B-F, poster section 12.
  2. Muenz, M. et al. (2009). Eradication of colon cancer stem cells by EpCAM/CD3-bispecific BiTE antibody MT110. AACR Annual Meeting 2009, abstract no. 3250; to be presented in session ‘Immunology 5′ on April 21, 2009, 8:00 AM in Hall B-F, poster section 12.
  3. Kischel, R. et al. (2009). Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. AACR Annual Meeting 2009, abstract no. 3252; to be presented in session ‘Immunology 5′ on April 21, 2009, 8:00 AM in Hall B-F, poster section 12.
  4. Oberst, M. et al. (2009). In vitro pharmacological comparison of a carcinoembryonic antigen (CEA; CEACAM5; CD66e)/CD3 bispecific cynomolgus-reactive BiTE antibody (CyS111) biosimilar with the clinical candidate MEDI-565 (MT111). AACR Annual Meeting 2009, abstract no. 3247; to be presented in session ‘Immunology 5′ on April 21, 2009, 8:00 AM in Hall B-F, poster section 12.
  5. Torisu-Itakura, H. et al. (2009). Anti-tumor activity of a T cell-engaging MCSP-specific BiTE antibody at very low effector to target ratios: A new approach to treat metastatic melanoma. AACR Annual Meeting 2009, abstract no. 3248; to be presented in session ‘Immunology 5′ on April 21, 2009, 8:00 AM in Hall B-F, poster section 12.
  6. Aigner, M. et al. (2009). Effective in vitro lysis of human melanoma cell lines by T lymphocytes redirected with a MCSP/CD3-bispecific single-chain antibody construct is independent of the expression of tumor-associated antigens gp100, MART-1, tyrosinase and NY-ESO1. AACR Annual Meeting 2009, abstract no. 4152; to be presented in session ‘Immunology 6′ on April 21, 2009, 1:00 PM in Hall B-F, poster section 11.

Abstracts can be accessed at http://www.aacr.org.

About Micromet

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company’s novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient’s own immune system to eliminate cancer cells or other disease related cells. Four of the Company’s antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company’s lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin’s lymphoma. Micromet’s second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company’s third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company’s preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the return of development and commercialization rights to blinatumomab, the future development of blinatumomab and a new BiTE antibody binding to CD19, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, our plans regarding future presentations of clinical data, our expectations of timing for the publication of results from our research and development programs, our ability to draw down on the Committed Equity Financing Facility with Kingsbridge, and our plans regarding collaborations and other partnering activities. You are urged to consider statements that include the words “ongoing,” “may,” “will,” “believes,” “potential,” “expects,” “plans,” “anticipates,” “intends,” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the SEC on November 6, 2008, as well as other filings by the company with the SEC.

SOURCE Micromet, Inc.


Source: newswire



comments powered by Disqus